(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 June 2013 (20.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/088114 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01) *A61K 35/14* (2006.01)

(21) International Application Number:
PCT/GB2012/050896

(22) International Filing Date:
23 April 2012 (23.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/569,577 12 December 2011 (12.12.2011) US

(71) Applicants *(for all designated States except US)*: **CELL MEDICA LIMITED** [GB/GB]; 27 Fitzroy Square, London W1T 6ES (GB). **BAYLOR COLLEGE OF MEDICINE** [US/US]; One Baylor Plaza, Houston, Texas 77030 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROONEY, Cliona M.** [US/US]; Center for Cell and Gene Therapy, Department of Pediatrics, 1102 Bates St, Suite 1770, Houston, Texas 77030 (US). **LEEN, Ann M.** [IE/US]; Center for Cell and Gene Therapy, Department of Pediatrics, 1102 Bates St, Suite 1770, Houston, Texas 77030 (US). **VERA, Juan F.** [CO/US]; Center for Cell and Gene Therapy, Baylor College of Medicine BCM 315, 1102 Bates St, Suite 1770, Houston, Texas 77030 (US). **NGO, Minhtran V.** [US/US]; Center for Cell and Gene Therapy, Department of Pediatrics-Hematology and Oncology, Baylor College of Medicine, 1102 Bates St, Suite 1770, Houston, Texas 77030 (US). **KNAUS, Rainer Ludwig** [DE/GB]; Cell Medica Ltd, 27 Fitzroy Square, London W1T 6ES (GB).

(74) Agent: **STERLING IP**; Orion House, Bessemer Road, Welwyn Garden City, Hertfordshire AL7 1HE (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: PROCESS OF EXPANDING T CELLS

FIGURE 2: Diagram of the alternative methods demonstrated in this application of novel superior protocols for the generation of EBV specific T cells.



(57) Abstract: The present disclosure relates to a novel process for *in vitro* expansion of autologous or allogenic antigen specific T cellscomprising the steps:a)culturing a population of autologous PCMB cells in the presence of: i) dendritic cells which have been pulsed with a peptide/peptide mix relevant to a target antigen OR a peptide/peptide mix relevant to a target antigen, and ii) at least one cytokine, and b)culturing a population of T cells from step a)in the presence of: i) dendritic cells which have been pulsed with a peptide/peptide mix relevant to a target antigen OR autologous antigen presenting T cells (T-APC's) cells which have been pulsed with a peptide/peptide mix relevant to a target antigen and an artificial co-stimulatory factor, and ii) optionally a cytokine, and characterized in that the process does not employ live virus and/or viral vectors or the use of DNA or RNA encoding antigens or recombinant target antigens in the expansion of the relevant T cell population. The disclosure also extends to cell populations obtained from said process, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent patients.

WO 2013/088114 A1

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

— *with sequence listing part of description (Rule 5.2(a))*